BiotechTube
Gossamer Bio

Gossamer Bio

GOSSPhase 3
gossamerbio.com

Gossamer Bio is a publicly traded biotech company dedicated to improving the lives of patients with rare diseases, primarily through the development of its lead candidate, seralutinib. The company's strategy leverages an inhaled delivery mechanism to target pulmonary hypertension directly in the lungs, aiming to overcome limitations of systemic therapies. With a seasoned leadership team experienced in drug development and company building, Gossamer is advancing its pivotal Phase 3 PROSERA study in PAH, positioning itself as a potential innovator in a high-need therapeutic area with significant market opportunity.

Market Cap
$99.1M
-67.0% period
Pipeline
12
3 in Phase 3
Patents
—
Publications
—

GOSS · Stock Price

USD 0.420.86 (-67.00%)

Historical price data

AI Company Overview

Gossamer Bio is a publicly traded biotech company dedicated to improving the lives of patients with rare diseases, primarily through the development of its lead candidate, seralutinib. The company's strategy leverages an inhaled delivery mechanism to target pulmonary hypertension directly in the lungs, aiming to overcome limitations of systemic therapies. With a seasoned leadership team experienced in drug development and company building, Gossamer is advancing its pivotal Phase 3 PROSERA study in PAH, positioning itself as a potential innovator in a high-need therapeutic area with significant market opportunity.

Pulmonary HypertensionRare Diseases

Technology Platform

Inhaled dry powder delivery of a tyrosine kinase inhibitor (PDGFRα/β, CSF1R, c-KIT) designed for localized treatment in the lungs to minimize systemic exposure.

Pipeline

12
12 drugs in pipeline3 in Phase 3
DrugIndicationStageWatch
SeralutinibPulmonary Arterial HypertensionPhase 3
Placebo + SeralutinibPulmonary Arterial HypertensionPhase 3
Placebo + SeralutinibPulmonary Hypertension Associated With Interstitial Lung DiseasePhase 3
GB004 + PlaceboUlcerative ColitisPhase 2
GB001 + PlaceboAsthmaPhase 2

Funding History

4
Total raised:$746.6M
PIPE$125MDec 15, 2020
IPO$291.6MFeb 7, 2019
Series B$230MSep 15, 2018
Series A$100MJan 15, 2018

Opportunities

The primary opportunity is addressing the large, unmet need in both PAH and PH-ILD with a novel, locally-acting therapy.
Success in PAH could lead to expansion into other forms of pulmonary hypertension.
The inhaled delivery platform may also have utility for other pulmonary diseases.

Risk Factors

Existential risk from failure of the Phase 3 PROSERA trial.
Intense competition in PAH from new mechanism drugs.
Challenges in building a commercial organization or securing a favorable partnership as a single-asset company.
Dependence on future capital raises.

Competitive Landscape

Competes against established vasodilator therapies in PAH and novel agents like Merck's sotatercept. In PH-ILD, faces competition from other developers but benefits from a lack of approved therapies. Differentiation hinges on the unique inhaled mechanism targeting fibrosis and remodeling.